Core Viewpoint - The company focuses on developing pediatric medications, emphasizing the need for tailored drug solutions for children and maintaining high-quality standards in design and production [2] Group 1: Product Development - The subsidiary, Dain Pharmaceutical, has received drug registration certificates for sodium valproate oral solution and sustained-release clonidine tablets [2] - The company has initiated clinical trials for the inhalation aerosol of ipratropium bromide, indicating a commitment to expanding its product pipeline [2] Group 2: Strategic Focus - The company aims to enhance its core competitiveness by continuously developing 1-2 new pediatric-specific medications each year [2] - The research and development efforts are directed towards addressing clinical needs in mental health, respiratory, and digestive fields, aligning with children's health and nutritional requirements [2]

Group 1 - The company, 华特达因 (000915.SZ), has stated that it currently has no overseas business operations [1]

Core Viewpoint - The company Huate Dain (000915.SZ) has begun online sales of its children's melatonin product, Manlejing, on platforms such as JD.com and Alibaba, with plans for offline sales in hospitals across China [1] Group 1 - The company reports that its production, operations, and sales are currently normal [1] - The company's stock price fluctuations are influenced by various macroeconomic factors [1] - The company aims to focus on its core business to enhance its competitive strength and deliver good operating results to investors [1]

Group 1 - The company, Shandong Huate Dain Health Co., Ltd., has completed the bankruptcy liquidation and deregistration process for its wholly-owned subsidiary, Shandong Huate Information Technology Co., Ltd. [1][2] - The bankruptcy application was filed by Huate Information on October 20, 2023, and the court accepted the application, appointing a manager for the liquidation process [2][4] - The court declared Huate Information bankrupt on December 11, 2024, and the bankruptcy proceedings were concluded on August 13, 2025 [3][4] Group 2 - The deregistration of Huate Information will not affect the company's normal production and profitability, and it aligns with the company's strategy to focus on children's health pharmaceuticals [4] - The company has made necessary accounting adjustments related to long-term equity investments and receivables associated with Huate Information [4]

证券代码：000915 证券简称：华特达因 公告编号：2026-002 山东华特达因健康股份有限公司 关于原全资子公司破产清算事项的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 2026年1月29日，济南市天桥区行政审批服务局出具《登记通知 书》（天桥）登字[2026]第004594号，对山东华特信息科技有限公 司（以下简称"华特信息公司"）提交的注销登记申请予以登记。 华特信息公司破产清算及市场主体注销登记程序已办理完成。 一、华特信息公司破产清算情况 法院《民事裁定书》（〔2023〕鲁0105破3号之一），宣告华特信息 公司破产。 2025年8月13日，公司在巨潮资讯网披露了《关于原全资子公司 破产清算事项的进展公告》（公告编号： 2025-037），公司收到法 院《民事裁定书》（〔2023〕鲁0105破3号之三），裁定终结山东华 特信息科技有限公司破产程序。 二、本次事项对上市公司的影响 公司已根据相关会计准则对与华特信息公司相关的长期股权投 资、往来款项等进行了相应的会计处理，本次华特信息公司的注销 不会影响公司正常生产经营和盈利能力，有利 ...

证券日报网讯 1月20日，华特达因在互动平台回答投资者提问时表示，公司严格按照中国证监会和深交 所的相关要求组织年度报告编制和披露工作，2025年度预计经营业绩不属于应当披露业绩预告的范围， 年度报告预约披露时间为2026年4月24日。 （文章来源：证券日报） ...

Core Viewpoint - The company is focusing on its core business by developing a systematic product matrix aimed at children's clinical needs and nutritional health requirements [1] Group 1: Product Development - The company is extending its product categories based on the "Yike Xin" brand to create a matrix of pediatric medications that includes areas such as nutrition, respiratory, digestive, and mental health [1] - The company is also expanding the "Yike Xin" brand to cover five major areas in children's health: basic nutrition, eye and brain development, gut health, immune health, and skin care [1] Group 2: Strategic Focus - The company aims to continuously enrich its range of children's medicines and health products to meet the diverse nutritional and health needs of adolescents across different age groups [1] - The strategy is designed to strengthen and develop the company's core competitive capabilities and operational performance [1]

人民财讯1月20日电，华特达因（000915）1月20日在互动平台表示，公司目前与雀巢公司没有业务往 来。 ...

Group 1 - The core point of the article is that Huate Dain (000915) is set to officially launch its melatonin granule product, Manlejing, for online sales on platforms like Alibaba and JD this week, following prior interest reservations [1] - The product will also gradually enter hospitals across various regions in China for sales [1]

证券日报网讯1月13日，华特达因（000915）在互动平台回答投资者提问时表示，公司褪黑素颗粒产品 曼乐静本周即可在阿里和京东线上根据医生处方购买，后续将陆续进入国内各地医院销售。 ...